Hepatitis C is as infectious disease that is caused by hepatitis C virus (HCV). The infection primarily affects liver and is commonly asymptomatic in nature. However, in some chronic cases it leads to scarring of liver and cirrhosis. People suffering from hepatitis C infection may even suffer from liver cancer, liver failure, esophageal or gastric varices. Hepatitis C infection primarily spreads through blood to blood contact. For instance, using poorly sterilized medical equipment and unchecked blood transfusion may lead to hepatitis C infection. In addition, intravenous drug use, sexual intercourse, body modification such as tattooing and sharing personal things such as razors and toothbrushes may lead to transmission of hepatitis C infection. Various types of hepatitis C treatments are available in the market, such as medication, surgery and alternative medicines. The global market for hepatitis C treatment is growing at a significant rate due to increasing number of cases with hepatitis C infection. In addition, growing population and growing awareness for improved healthcare facilities is increasing the global market for hepatitis C treatment.
North America dominates the global hepatitis C treatment market due to increasing prevalence of hepatitis C infection cases and improved healthcare facilities in the region. In addition, government initiatives and more awareness among the people are some of the major factors driving the hepatitis C treatment market. Asia, followed by Europe, is expected to experience high growth rate in the next few years in hepatitis C treatment market. China and India are expected to be the fastest growing hepatitis C treatment markets in Asian region. This is due to large investment by various major companies in these countries. Some of the key driving forces for hepatitis C treatment market in emerging countries are large pool of patients, rising government funding and improvement in the healthcare facilities.
One of the major factors driving the global hepatitis C treatment market includes increasing number of hepatitis C infection cases. In addition, increasing awareness about the treatment of disease and government initiatives in the field are driving the global hepatitis C treatment market. However, some of the factors such as high cost and people willing to stick to conservative methods are restraining the global hepatitis C treatment market.
Growing demographics and economies in the developing countries such as India and China are expected to offer good opportunities for global hepatitis C treatment market. In addition, growing awareness and innovation of some new type of medications with better efficiency are expected to offer good opportunity for global hepatitis C treatment market. Side effects associated with the use of medications for hepatitis C infection are some of the major challenges faced by global pediatric interventional cardiology devices market. One of the latest trends that have been observed in global hepatitis C treatment market includes companies involved in mergers and acquisitions. In addition, it has been observed that companies are involved in R&D and product launches of more efficient products, for instance, interferon-free therapies. Some of the major companies involved in global hepatitis C treatment market are F. Hoffmann-La Roche, Gilead Sciences, Johnson & Johnson, Merck and Vertex Pharmaceuticals. Some other companies dealing having significant presence in the global hepatitis C treatment market are Novartis, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb and Mitsubishi Tanabe Pharma.
Key geographies evaluated in this report are:
Key features of this report